Company Description
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein.
The company’s NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration.
It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.
The company’s platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications.
Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
| Country | United States |
| Founded | 2004 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Jeffrey Frelick |
Contact Details
Address: 2 Burlington Woods Drive, Suite 100 Burlington, Massachusetts 01803 United States | |
| Phone | 781 552 4452 |
| Website | bonebiologics.com |
Stock Details
| Ticker Symbol | BBLG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001419554 |
| CUSIP Number | 098070303 |
| ISIN Number | US0980705018 |
| Employer ID | 42-1743430 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey Frelick | Chief Executive Officer and President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 13, 2024 | 8-K | Current Report |
| Dec 13, 2024 | 424B5 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 21, 2024 | 8-K | Current Report |
| Oct 4, 2024 | 8-K | Current Report |
| Sep 27, 2024 | 8-K | Current Report |
| Sep 27, 2024 | 424B5 | Filing |
| Sep 19, 2024 | 8-K | Current Report |